Particle Sciences partners with Encube Ethicals to develop novel vaginal rings
The partnership will focus on rings for the administration of existing approved drugs, improving drug effectiveness and patient compliance.
Contract development and manufacturing organization (CDMO), Particle Sciences, a Lubrizol LifeSciences company, has announced its partnership with leading Indian contract manufacturing organization (CMO), Encube Ethicals.
Under the partnership the two companies will develop innovative intravaginal rings with the intent to out-license to biopharmaceutical marketing partners. The partnership will focus on rings for the administration of existing approved drugs, improving drug effectiveness and patient compliance. The use of drug-eluting devices to provide sustained-release dosage forms has seen continued growth due to the ability to provide constant, localized, site-specific drug delivery. The market continues to be of interest as these devices can improve patient compliance, one of the greatest challenges in healthcare today.
Both parties will leverage each other’s drug development and manufacturing strengths: Particle Sciences has a proven track record and extensive expertise in the development and manufacturing of intravaginal ring devices and complex formulations, while Encube Ethicals has strong capabilities in developing complex topical and transdermal delivery systems, with two decades of experience in commercial manufacturing of Topical products for a variety of markets, including women’s health for multiple countries.
The project is Particle Sciences’ latest in the complex generics space using the 505(b)(2) US Food and Drug Administration (FDA) regulatory pathway to develop new drugs that better meet the requirements of patients and physicians. Dr. Barbara Morgan, general manager of Particle Sciences said: “Our collaboration with Encube Ethicals is an important step in our work on complex pharmaceuticals and particularly toward our efforts to accelerate improved therapeutics through the use of the 505(b)(2) pathway.”
Mr Mehul Shah, founder and managing director of Encube Ethicals said: “We are deeply invested in finding innovative ways to deliver drugs that make the patient’s experience significantly better and safer. We hope to leverage Encube’s experience in Topical products development and manufacturing to bring impactful breakthrough innovations to the market. We are delighted to partner with Particle Sciences’ extremely talented team and excited to see the possibilities the effort creates.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...